Related Experiment Video

Updated: Jan 29, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K

The Effect of Sacubitril/Valsartan on Mood and Cognitive Function in Patients with Heart Failure with Reduced

Fahad Al Kindi1,2, Raya Al Maskari1,3, Fatma Al Mahruqi4

  • 1Medical Research Center, Sultan Qaboos University, Muscat 123, Oman.

Brain Sciences
|January 28, 2026
PubMed

Insights

Sacubitril/valsartan may improve mood and abstract reasoning in heart failure patients, independent of cardiac function improvements. Further research is needed to confirm these neurocognitive benefits.

Area of Science:

  • Cardiology
  • Neuropsychology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) presents significant neuropsychological challenges, including cognitive deficits and mood disorders.
  • Sacubitril/valsartan, known for cardiovascular benefits, has underexplored effects on cognitive and emotional health, especially in Middle Eastern populations.

Purpose of the Study:

  • To assess the impact of sacubitril/valsartan on cognitive function, mood, and intellectual capacity in adult HFrEF patients.
  • To investigate potential neurocognitive benefits of sacubitril/valsartan in an HFrEF cohort.

Main Methods:

  • An idiographic study design involving adult HFrEF patients initiating sacubitril/valsartan.
  • Cognitive and mood assessments using Al Khoudh Cognitive Test, PHQ-9, and Raven's Progressive Colored Matrices at baseline and 3 months.

Main Results:

  • Significant improvements observed in left ventricular ejection fraction (LVEF) and depression severity after 3 months.
  • A non-significant trend towards improved abstract reasoning was noted, with verbal fluency showing the largest improvement among cognitive subdomains.
  • No significant association was found between LVEF improvements and changes in mood or cognitive function.

Conclusions:

  • Preliminary evidence suggests potential short-term improvements in mood and reasoning in HFrEF patients treated with sacubitril/valsartan.
  • Observed neurocognitive changes were not directly linked to improvements in cardiac function.
  • Further investigation in larger, diverse populations is warranted to explore the neurocognitive benefits of sacubitril/valsartan.

Keywords:
HFrEFcognitive functionheart failuremoodsacubitril/valsartan

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272